First-line (1L) nivolumab (NIVO) + ipilimumab (IPI) in patients (pts) with microsatellite instability-high/mismatch repair deficient (MSI-H/dMMR) metastatic colorectal cancer (mCRC): 64-month (mo) follow-up from CheckMate 142.
Publication/Presentation Date
5-2023
Published In/Presented At
First-line (1L) nivolumab (NIVO) + ipilimumab (IPI) in patients (pts) with microsatellite instability-high/mismatch repair deficient (MSI-H/dMMR) metastatic colorectal cancer (mCRC): 64-month (mo) follow-up from CheckMate 142.. JCO 41, 3550-3550(2023).
DOI:10.1200/JCO.2023.41.16_suppl.3550Disciplines
Medicine and Health Sciences
Department(s)
Department of Medicine, Lehigh Valley Topper Cancer Institute
Document Type
Article
COinS